A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Assess the disease control rate (DCR) at 16 weeks for patients treated with SGI-110 after failure of sorafenib
Percentage of patients achieving a best overall response of complete response or partial response and stable disease at 16 weeks
18 months
Yes
United States: Food and Drug Administration
SGI-110-03
NCT01752933
December 2012
May 2014
Name | Location |
---|---|
Swedish Cancer Institute | Seattle, Washington 98104 |